Business Context and Reporting Period
This Form 6-K filing by Mereo Biopharma Group Plc, dated April 30, 2019, announces the publication of its Annual Report and Accounts for the year ended December 31, 2018. Mereo is a clinical-stage, UK-based biopharmaceutical company focused on rare diseases. The company's strategy involves selectively acquiring product candidates with substantial data packages. Following a merger with OncoMed, the pipeline now includes six candidates, with randomized Phase 2 trials commenced for four of them.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a notification of the availability of the Annual Report and Form 20-F, which contain the detailed financial statements for the year ended December 31, 2018.
Material Changes and Pipeline Updates
- BPS-804 (Osteogenesis Imperfecta): Enrollment of 112 adult patients in a Phase 2b dose-ranging study was completed in October 2018. Initial data is expected in Q2 2019, with top-line data in late 2019. A pediatric Phase 3 study design has been approved by the EMA.
- MPH-966 (Alpha-1 Antitrypsin Deficiency): Dosing of the first patient in a Phase 2 dose-ranging study in the U.S. has begun, with data expected around the end of 2019.
- BCT-197 (COPD): Following positive Phase 2 data in May 2018, the company outlined a pivotal Phase 3 study after a successful Phase 2 Type B meeting with the FDA.
- BGS-649 (Hypogonadotropic Hypogonadism): Positive top-line Phase 2b data was announced in March 2018, with positive safety extension results in December 2018.
- Navicixizumab: Completed Phase 1a; currently in a Phase 1b combination trial for platinum-resistant ovarian cancer, which recently completed enrollment.
- Etigilimab: Completed Phase 1a; currently in a Phase 1b combination study with nivolumab. Celgene holds an option to license this asset.
Outlook, Risks, and Contingencies
Contingency: Celgene has the option to obtain an exclusive license to develop and commercialize Etigilimab. If Celgene exercises this option, Mereo (via its subsidiary OncoMed) is eligible to receive a $35 million opt-in payment.
Outlook: Management anticipates initial data for BPS-804 in Q2 2019 and data for MPH-966 by the end of 2019. The company is advancing multiple candidates toward pivotal Phase 3 studies.
Investor Verification Checklist
- Verify the full financial statements (revenue, cash burn, and liquidity) in the referenced Annual Report and Form 20-F, as they are not included in this summary.
- Confirm the timeline for the release of initial data for the BPS-804 Phase 2b study (expected Q2 2019).
- Monitor the status of Celgene's decision regarding the Etigilimab license option and the potential $35 million payment.
- Review the specific endpoints and design of the pivotal Phase 3 study for BCT-197 following the FDA Type B meeting.